N Deborah Friedman1, Joanne H Green2, Hanna M Weber2, Shiny Stephen2, Stephen E Lane3, Alvin Y Ting4, Jonathan P Watson5. 1. Department of Infectious Diseases, Geelong, Victoria, Australia ; Department of Medicine, Geelong, Victoria, Australia. 2. Deakin University School of Medicine, Geelong, Victoria, Australia. 3. Department of Medicine, Geelong, Victoria, Australia ; Deakin University School of Medicine, Geelong, Victoria, Australia. 4. Department of Gastroenterology, Barwon Health, Geelong, Victoria, Australia. 5. Department of Medicine, Geelong, Victoria, Australia ; Department of Gastroenterology, Barwon Health, Geelong, Victoria, Australia ; Deakin University School of Medicine, Geelong, Victoria, Australia.
Abstract
BACKGROUND: Published clinical trials of the treatment of HCV are largely multicentre prospective pharmaceutical trials. Patients in clinical trials tend to have more favorable outcomes than patients in the 'real-world', due to strict patient selection and differences in treatment conditions and available resources. OBJECTIVES: To assess the outcomes of Hepatitis C infected patients treated at the Barwon Health Liver Clinic with combination Pegylated interferon (PEG-IFN) and Ribavirin (RBV) therapy and to determine factors associated with a treatment response. METHODS: Retrospective review of patients who received treatment for Hepatitis C at our institution's Liver Clinic from January 2001-September 2011. Patient demographics, comorbidities, treatment-related parameters and side effects were extracted from medical records and analyzed. RESULTS: A total of 190 patients (120 male, 70 female) with a mean age of 42.8 years (range 20-68 years) commenced treatment. The most common genotype was genotype 3 (48.9%), followed by genotype 1 (42.6%). 150 of 190 patients (78.9%) completed treatment and had end of treatment data available. 107 of 182 patients, (58.8%) for whom sustained virologic response (SVR) rate data was available achieved an SVR. Overall response rates were; 46.9%, 68.8% and 62.4% in genotypes 1, 2 and 3 respectively. The response rate was significantly lower in 29 patients with documented cirrhosis (20.7%). Age, diabetes and alcohol abuse did not predict treatment response in our cohort. Side effects reported in 81.6% of patients included general malaise, hematological disturbance and psychiatric issues, and necessitated cessation of therapy in 16 patients (8.4%) and dose reduction in 26 patients (13.7%). CONCLUSIONS: Response rates to combination PEG-IFN and RBV therapy at our institution are comparable to other 'real-world' and pharmaceutical registration trials. Side effects of combination therapy were prominent but resulted in fewer discontinuations of therapy compared to pharmaceutical trials.
BACKGROUND: Published clinical trials of the treatment of HCV are largely multicentre prospective pharmaceutical trials. Patients in clinical trials tend to have more favorable outcomes than patients in the 'real-world', due to strict patient selection and differences in treatment conditions and available resources. OBJECTIVES: To assess the outcomes of Hepatitis C infectedpatients treated at the Barwon Health Liver Clinic with combination Pegylated interferon (PEG-IFN) and Ribavirin (RBV) therapy and to determine factors associated with a treatment response. METHODS: Retrospective review of patients who received treatment for Hepatitis C at our institution's Liver Clinic from January 2001-September 2011. Patient demographics, comorbidities, treatment-related parameters and side effects were extracted from medical records and analyzed. RESULTS: A total of 190 patients (120 male, 70 female) with a mean age of 42.8 years (range 20-68 years) commenced treatment. The most common genotype was genotype 3 (48.9%), followed by genotype 1 (42.6%). 150 of 190 patients (78.9%) completed treatment and had end of treatment data available. 107 of 182 patients, (58.8%) for whom sustained virologic response (SVR) rate data was available achieved an SVR. Overall response rates were; 46.9%, 68.8% and 62.4% in genotypes 1, 2 and 3 respectively. The response rate was significantly lower in 29 patients with documented cirrhosis (20.7%). Age, diabetes and alcohol abuse did not predict treatment response in our cohort. Side effects reported in 81.6% of patients included general malaise, hematological disturbance and psychiatric issues, and necessitated cessation of therapy in 16 patients (8.4%) and dose reduction in 26 patients (13.7%). CONCLUSIONS: Response rates to combination PEG-IFN and RBV therapy at our institution are comparable to other 'real-world' and pharmaceutical registration trials. Side effects of combination therapy were prominent but resulted in fewer discontinuations of therapy compared to pharmaceutical trials.
Entities:
Keywords:
DAAs, directly acting agents; ETR, end of treatment response; HCV, hepatitis C virus; IVDU, intravenous drug use; NSW, new South Wales; PCR, polymerase chain reaction; PEG-IFN, pegylated interferon; RBV, ribavirin; RNA, ribonucleic acid; SVR, sustained virologic response; hepatitis C; peginterferon alfa-2a; peginterferon alfa-2b; ribavirin
Authors: Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Dongliang Ge; Jacques Fellay; Kevin V Shianna; Thomas Urban; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; William M Lee; Robert Reindollar; John W King; Paul Y Kwo; Reem H Ghalib; Bradley Freilich; Lisa M Nyberg; Stefan Zeuzem; Thierry Poynard; David M Vock; Karen S Pieper; Keyur Patel; Hans L Tillmann; Stephanie Noviello; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; David B Goldstein; John G McHutchison Journal: Gastroenterology Date: 2010-04-24 Impact factor: 22.682
Authors: Wendy S C Cheng; Stuart K Roberts; Geoffrey McCaughan; William Sievert; Martin Weltman; Darrell Crawford; William Rawlinson; Philippa S Marks; James Thommes; Bishoy Rizkalla; Motoko Yoshihara; Gregory J Dore Journal: J Hepatol Date: 2010-06-16 Impact factor: 25.083
Authors: T Witthoeft; D Hueppe; C John; J Goelz; R Heyne; B Moeller; G Teuber; S Wollschlaeger; A Baumgarten; K-G Simon; G Moog; N Dikopoulos; S Mauss Journal: J Viral Hepat Date: 2010-02-11 Impact factor: 3.728
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: Heather F Gidding; Matthew G Law; Janaki Amin; George Ostapowicz; Martin Weltman; Graeme A Macdonald; Joe J Sasadeusz; Paul A W Haber; Jacob George; Gregory J Dore Journal: Med J Aust Date: 2012-06-04 Impact factor: 7.738
Authors: Paul Marotta; Dietrich Hueppe; Elmar Zehnter; Paul Kwo; Ira Jacobson Journal: Clin Gastroenterol Hepatol Date: 2009-05-15 Impact factor: 11.382
Authors: Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill Journal: Ann Intern Med Date: 2004-03-02 Impact factor: 25.391
Authors: Henry N Luma; Servais A F B Eloumou; Dominique N Noah; B Aude Eyenga; Georges Nko'Ayissi; T Sylvie Taku; Agnes Malongue; Olivier Donfack-Sontsa; Ivo C Ditah Journal: J Clin Exp Hepatol Date: 2018-01-12
Authors: Urbano Sbarigia; Tom R Denee; Norris G Turner; George J Wan; Alan Morrison; Anna S Kaufman; Gary Rice; Geoffrey M Dusheiko Journal: Infect Drug Resist Date: 2016-05-27 Impact factor: 4.003